PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the pilot study is to determine activity of PAC-1 and nivolumab
combination in subjects with metastatic renal cell carcinoma previously treated with immune
checkpoint inhibitor therapy as assessed by objective response rate (ORR) using RECIST 1.1
criteria.